1. Personalized Therapy in Relapsed or Refractory CLL

4. IWCLL Criteria for Treating CLL

5. Other Considerations at Relapse

6. Risk Factors at Relapse

7. IGHV Status Affects Clinical Course

8. Case 1: 65-Year-Old Man

9. Assessing This Patient's Options

10. TP53 Mutation/del(17p) and CIT

11. Monoclonal Antibodies and del(17p)

12. Efficacy of Ibrutinib in del(17p)

13. Safety of Ibrutinib

14. Additional Considerations for Novel Agents

15. Overall Findings From RESONATE

16. Efficacy of Venetoclax in del(17p)

17. Safety of Venetoclax in Phase 2 Trial

18. TLS With Venetoclax

19. PI3K-δ Inhibitor Idelalisib

20. Case 2: 43-Year-Old Man

21. Considerations for Sequencing Therapy

22. Investigational Agents for Refractory CLL

23. Additional Considerations for Sequencing Therapy

24. Minimal Residual Disease

25. Case 3: 77-Year-Old Woman

26. Assessing This Patient's Options

27. Prolonged Lymphocytosis

28. Summary of Safety Concerns With Novel Agents

29. Concluding Remarks

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)

33. Abbreviations (cont)